Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name MEG3
   Synonyms MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1
   Region GRCh38_14:100779410-100861031    Sequence
   Ensembl ENSG00000214548
   RefSeq NR_002766
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name lung cancer
   ICD-0-3 C34  
   Methods qPCR, RNAi, Western blot, MTT assay etc.
   Sample cell lines (A549 and A549/DDP)
   Expression Pattern down-regulated
   Function Description

The present study detected that the expression levels of Meg3 were significantly lower in cisplatin-resistant A549/DDP lung cancer cells, compared with those in parental A549 cells. Furthermore, upregulation of Meg3 was able to re-sensitize the A549/DDP cells to cisplatin in vitro. Whereas downregulation of Meg3, by RNA interference, decreased the sensitivity of A549 cells to cisplatin. The results of the present study also demonstrated that the Meg3-mediated chemosensitivity enhancement was associated with the induction of cell-cycle arrest and increased apoptosis, through regulation of p53, B-catenin and survivin, which is a target gene of the WNT/B-catenin signaling pathway.

   Pubmed ID 26059239
   Year 2015
   Title Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/B-catenin signaling pathway.
   External Links
   Links for  MEG3 GenBank       HGNC       lncrnadb       Noncode
   Links for  lung cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.